The FDA recorded a supplement dated 2 September 2026 to Pfizer's new drug application for abrocitinib (Cibinqo, NDA 213871). The record does not say what the supplement changes.
Abrocitinib is an oral JAK1 inhibitor licensed for atopic dermatitis, not for inflammatory arthritis. It is relevant to rheumatologists mainly because JAK inhibitors share class labelling on serious infections, malignancy, major cardiovascular events and thrombosis. Nothing in this record indicates a new indication or safety communication. The Indian regulatory position is not stated.
- Treat this as a licence supplement, not a new indication or safety alert.
- Ask patients about JAK inhibitors prescribed by dermatology when reviewing immunosuppression.
- Apply JAK class precautions — age, smoking, cardiovascular and thrombotic risk — whichever specialty prescribes.
- Watch for any published label change before altering practice.
Why it matters
Patients may be on a JAK inhibitor from another specialty that rheumatology needs to know about.
Don't overread it
A licence supplement is not a new indication or a safety communication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free